NeuroSense Therapeutics Ltd
NRSNHealthcare·Biotechnology·Israel·Nano·NASD·Nov 13 • 6:01 AM ET
1.77+0.01 (0.57%)
2026-11-13 13:21 CET
Market cap
$3.36M
Revenue, TTM
0.00 USD m
Net income, TTM
-11.13 USD m
Free cash flow, TTM
-7.68 USD m
EPS diluted, TTM
-8.73
Price
NRSN against its 20, 50 and 200-day averagesPatternshover a marker to name it
93.0% under the 52-week high of 25.40 on 19 Nov 2025. 52-week low 1.10 on 2 Nov 2026. Last 15 sessions, 150.0% high to low
Volume 0.12× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%) — not on the tape: Return on Equity: Over +15%
Quality 0 of 5 — not on the tape: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25; Current Ratio: Over 1
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
NRSN52-week range, 3% of the way up
1.1025.40
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
| Employees | 16 |
|---|---|
| IPO | Dec 09, 2021 |
| Beta | 1.73 |
| ATR, 14d | 0.40 |
| Rel volume | 0.12 |
| Short float | 2.09% |
| Insider own | 31.70% |
| Inst own | 0.45% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $3.36M |
| Enterprise Value | - |
| Income | - |
| Sales | - |
| Book / share | - |
| Cash / share | - |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 16 |
| IPO | Dec 09, 2021 |
Ratios
Earnings
| Earnings / share | - |
|---|---|
| Earnings next year | -4.67 |
| Earnings next quarter | - |
| Earnings this year | 42.61% |
| Earnings next year | 7.43% |
| Earnings growth, 5 years | 4.85% |
| Past earnings growth | 25.89% 21.42% |
| Past sales growth | - - |
| Earnings vs last year | 31.09% |
| Sales vs last year | - |
| Earnings vs last quarter | 59.58% |
| Sales vs last quarter | - |
| Earnings | Sep 02 |
| Surprise | 0.00% - |
Ownership
| Insiders own | 31.70% |
|---|---|
| Insider trades | 490.47% |
| Institutions own | 0.45% |
| Institution trades | -0.31% |
| Return on assets | - |
| Return on equity | - |
| Return on capital | - |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -11.61% |
| 50-day average | -57.25% |
| 200-day average | -85.24% |
Technical
| Shares out | 1.90M |
|---|---|
| Shares floating | 1.30M |
| Short / float | 2.09% |
| Short ratio | 0.85 |
| Short interest | 0.03M |
| 52-week high | 25.40 -93.0% |
| 52-week low | 1.10 +60.9% |
| Volatility | 21.03% 19.74% |
| Average range | 0.40 |
| Strength index | 32.57 |
| Market sensitivity | 1.73 |
| Relative volume | 0.12 |
| Avg Volume | 32.13K |
| Volume | 200 |
Performance
| Perf Week | 5.36% |
|---|---|
| Perf Month | -44.16% |
| Perf Quarter | -79.51% |
| Perf Half Y | -89.29% |
| Perf YTD | -88.49% |
| Perf Year | -90.35% |
| Perf 3Y | -82.26% |
| Perf 5Y | - |
| Perf 10Y | - |
| Recommendation | 2.33 |
| Target Price | 100.67 |
| Prev Close | 1.76 |
| Price | 1.77 |
| Change % | 0.57% |
Peers
Mkt capInsider trading
2 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Eisenberg Or | Chief Financial Officer | Jun 16 '26 | Buy | 0.80 | 250,000 | 200,000 | 1,504,050 | Jun 17 04:30 PM |
| Ben-Noon Alon | Chief Executive Officer | Jun 16 '26 | Buy | 0.80 | 250,000 | 200,000 | 4,534,233 | Jun 17 04:30 PM |
News
latest 14 of 200- NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data (PR Newswire) -28.14%
- NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 (PR Newswire) -9.75%
- NeuroSense Files U.S. Patent Application for Traumatic Brain Injury (PR Newswire) -13.19%
- NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones (PR Newswire)
- NeuroSense Provides Update on Nasdaq Listing Compliance (PR Newswire)
- NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference (PR Newswire) -26.62%
- NeuroSense Provides Business Update and Progress for the First Half of 2026 (PR Newswire) -6.08%
- NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire) -17.21%
- NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval (FinanceWire)
- NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS (PR Newswire)
- NeuroSense Issues CEO Letter to Shareholders (PR Newswire) -5.46%
- NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada (PR Newswire) -7.16%
- NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS (PR Newswire) -7.14%
- NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" (PR Newswire)
Quarterly earnings
2026Q2 EPS -3.900 matched -3.900, from -2.754 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-09-02 12:00 | -3.900 | -3.900 | -0.800 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2025Q2, year-ago quarter · EPS +41.6% · sales - | 2 EPS · 1 sales | Open -0.74% vs SPY +0.09%. Close -2.21% vs SPY +0.44% |
| 2025Q4ended 2025-12-31 | 2026-03-31 08:30 | -4.700 | -1.416 | -0.800 | 0.00 | 0.00 | EPS +231.9% · sales - | vs 2024Q4, year-ago quarter · EPS +487.5% · sales - | 2 EPS · 1 sales | Open -0.14% vs SPY +1.10%. Close +3.28% vs SPY +2.91% |
| 2025Q3ended 2025-09-30 | 2025-11-26 12:00 | -0.800 | -0.874 | -0.800 | 0.00 | 0.00 | EPS -8.5% · sales - | vs 2024Q3, year-ago quarter · EPS -66.7% · sales - | 1 | Open 0.00% vs SPY +0.39%. Close +12.50% vs SPY +0.69% |
| 2025Q2ended 2025-06-30 | 2025-08-01 08:30 | -2.754 | -4.452 | -2.800 | 0.00 | 0.00 | EPS -38.1% · sales - | vs 2024Q2, year-ago quarter · EPS +175.4% · sales - | 2 EPS · 1 sales | Open -2.78% vs SPY -0.91%. Close -40.00% vs SPY -1.64% |
| 2025Q1ended 2025-03-31 | 2025-05-28 12:00 | -2.086 | -2.086 | -2.100 | 0.00 | 0.00 | EPS 0.0% · sales - | vs 2024Q1, year-ago quarter · EPS -70.2% · sales - | 2 EPS · 1 sales | Open 0.00% vs SPY +0.07%. Close +3.95% vs SPY -0.58% |
| 2024Q4ended 2024-12-31 | 2025-04-07 16:30 | -0.800 | -3.000 | -1.560 | 0.00 | - | EPS -73.3% · sales - | vs 2023Q4, year-ago quarter · EPS -78.4% · sales - | 1 | Open +2.06% vs SPY +3.47%. Close -2.28% vs SPY -1.57% |
| 2024Q3ended 2024-09-30 | 2024-12-18 08:30 | -2.400 | -2.200 | -2.169 | - | - | EPS +9.1% · sales - | vs 2023Q3, year-ago quarter · EPS -366.7% · sales - | 1 | Open -0.92% vs SPY -0.05%. Close +4.59% vs SPY -2.98% |
| 2024Q2ended 2024-06-30 | 2024-08-28 12:00 | -1.000 | -3.700 | -0.949 | - | - | EPS -73.0% · sales - | vs 2023Q2, year-ago quarter · EPS -83.9% · sales - | 2 | Open -2.70% vs SPY -0.06%. Close -4.32% vs SPY -0.58% |
| 2024Q1ended 2024-03-31 | 2024-06-24 08:30 | -7.000 | -4.100 | -7.016 | - | - | EPS +70.7% · sales - | vs 2023Q1, year-ago quarter · EPS +6.1% · sales - | 2 | Open -6.35% vs SPY -0.03%. Close -5.87% vs SPY -0.33% |
| 2023Q4ended 2023-12-31 | 2024-04-05 08:30 | -3.700 | -4.000 | -3.836 | - | - | EPS -7.5% · sales - | vs 2022Q4, year-ago quarter · EPS -31.5% · sales - | 2 | Open +3.40% vs SPY +0.27%. Close -17.48% vs SPY +1.04% |
| 2023Q3ended 2023-09-30 | 2023-11-28 08:30 | 0.900 | -5.200 | 1.151 | - | - | EPS -117.3% · sales - | vs 2022Q3, year-ago quarter · EPS -117.3% · sales - | 1 | Open +5.86% vs SPY -0.09%. Close +5.83% vs SPY +0.10% |
| 2023Q2ended 2023-06-30 | 2023-08-16 08:30 | -6.200 | -5.900 | -7.671 | - | - | EPS +5.1% · sales - | vs 2022Q2, year-ago quarter · EPS +3.3% · sales - | 2 | Open +10.42% vs SPY -0.10%. Close -5.23% vs SPY -0.73% |
| 2023Q1ended 2023-03-31 | 2023-06-01 08:30 | -6.600 | -5.800 | -6.600 | - | - | EPS +13.8% · sales - | vs 2022Q1, year-ago quarter · EPS +37.5% · sales - | 1 | - |
| 2022Q4ended 2022-12-31 | 2023-03-22 08:30 | -5.400 | -5.600 | -5.347 | - | - | EPS -3.6% · sales - | vs 2021Q4, year-ago quarter · EPS +68.8% · sales - | 1 | - |
| 2022Q3ended 2022-09-30 | 2022-12-01 08:30 | -5.200 | - | -5.129 | - | - | EPS - · sales - | - | 1 | - |
| 2022Q2ended 2022-06-30 | 2022-08-31 08:30 | -6.000 | - | -6.033 | - | - | EPS - · sales - | - | 1 | - |
Annual earnings
2025FY EPS -8.800 missed -6.995, from -10.900 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 7.490 | - | - | 162.5 | 0.24 |
| 2029FYestimate | - | 13.185 | - | - | 21.40 | 0.13 |
| 2028FYestimate | - | -7.580 | - | - | 10.00 | - |
| 2027FYestimate | - | -4.675 | - | - | 0.00 | - |
| 2026FYestimate | - | -5.050 | - | - | 0.00 | - |
| 2025FY | -8.800 | -6.995 | -8.800 | 0.00 | 0.00 | - |
| 2024FY | -10.900 | -13.000 | -10.977 | 0.00 | - | - |
| 2023FY | -16.600 | -16.400 | -14.819 | - | - | - |
| 2022FY | -21.400 | -22.000 | -21.452 | - | - | - |
| 2021FY | -11.600 | -16.800 | -41.639 | - | - | - |
Quarterly results
2024Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -5.05 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-10-24 | -5.05 | 0.0% |
| 2026FY | S | per share | 2026-09-02 | 0.00 | - |
| 2026Q1 | S | per share | 2026-05-20 | 0.51 | +0.0% |
| 2026Q3 | S | per share | 2026-05-20 | 0.54 | -0.1% |
| 2026Q1 | E | per share | 2026-04-07 | -0.08 | +109.1% |
| 2026Q3 | E | per share | 2026-04-07 | -0.79 | -11.1% |
| 2026FY | R | per share | 2026-04-07 | -4.20 | +16.7% |
| 2026Q1 | R | per share | 2026-04-07 | -0.08 | - |
| 2026Q3 | R | per share | 2026-04-07 | -0.80 | - |
| 2025FY | E | per share | 2026-03-24 | -0.35 | -0.1% |
| 2025Q4 | E | per share | 2026-03-24 | -0.07 | +1.1% |
| 2025FY | S | per share | 2026-03-09 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-01 | 0.00 | - |
| 2025Q4 | R | per share | 2025-11-26 | -0.04 | 0.0% |
| 2025Q3 | E | per share | 2025-11-24 | -0.04 | 0.0% |
| 2025FY | R | per share | 2025-11-14 | -0.40 | +14.3% |
| 2025Q3 | R | per share | 2025-11-14 | -0.04 | -27.3% |
| 2025Q3 | S | per share | 2025-08-01 | 0.00 | - |
| 2025Q2 | E | per share | 2025-07-09 | -0.22 | -1.1% |
| 2025Q2 | R | per share | 2025-05-28 | -0.23 | 0.0% |
| 2025Q2 | S | per share | 2025-05-28 | 0.00 | - |
| 2025Q1 | E | per share | 2025-05-19 | -0.10 | -18.8% |
| 2025Q1 | R | per share | 2025-05-19 | -0.11 | -19.2% |
| 2025Q1 | S | per share | 2025-05-09 | 0.00 | - |
| 2024FY | E | per share | 2025-03-23 | -0.65 | +8.3% |
| 2024Q4 | E | per share | 2025-03-23 | -0.15 | +30.4% |
| 2024FY | R | per share | 2024-12-25 | -0.55 | 0.0% |
| 2024Q4 | R | per share | 2024-12-25 | -0.08 | 0.0% |
| 2024Q3 | E | per share | 2024-10-11 | -0.11 | -21.4% |
| 2024Q3 | R | per share | 2024-10-11 | -0.11 | -21.4% |
| 2024Q2 | E | per share | 2024-07-02 | -0.19 | -2.6% |
| 2024Q2 | R | per share | 2024-07-02 | -0.16 | -5.9% |
| 2024Q1 | E | per share | 2024-05-23 | -0.21 | +7.9% |
| 2024Q1 | R | per share | 2024-05-23 | -0.22 | +4.8% |
| 2023FY | E | per share | 2024-02-18 | -0.82 | 0.0% |
| 2023FY | R | per share | 2024-02-18 | -0.79 | 0.0% |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| EPS per share | -12.592 | -29.14 | -41.639 | -21.452 | -14.819 | -10.977 | -8.732 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 0 | 0 | 1 | 1 | 1 | 1 | 2 |
| Metric | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -5.347 | -6.6 | -7.671 | 1.151 | -3.836 | -7.016 | -0.949 | -2.169 | -0.078 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 23 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.02 | 0.020.0% | 0.020.0% | 0.02-77.8% | 0.09 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -0.02 | -0.02 | -0.02 | -0.02 | -0.09 | -0.00 | -0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 11.07 | 11.07+12.0% | 9.88-17.9% | 12.03-10.6% | 13.46+141.2% | 5.58+93.1% | 2.89+133.1% | 1.24 |
| Research and Development | 6.23 | 6.23+9.3% | 5.70-21.6% | 7.27+13.2% | 6.42+108.4% | 3.08+23.2% | 2.50+177.8% | 0.90 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -11.09 | -11.09 | -9.90 | -12.05 | -13.55 | -5.59 | -2.89 | -1.24 |
| Non-Operating Income (Expense) | -0.03 | -0.03 | -0.04-120.0% | 0.20+185.7% | 0.07 | -0.03-150.0% | 0.06+500.0% | 0.01 |
| Interest Expense | 0.01 | 0.01-96.8% | 0.31-31.1% | 0.45+2150.0% | 0.02-98.3% | 1.15 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | -0.05 | -2.19 | -1.17 | -2.73 | 0.00 | 0.00 |
| Net Income Before Taxes | -11.13 | -11.13 | -10.21 | -10.11 | -12.34 | -4.04 | -2.83 | -1.22 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -11.13 | -11.13 | -10.21 | -10.11 | -12.34 | -4.04 | -2.83 | -1.22 |
| Net Income From Continuing Operations | -11.13 | -11.13 | -10.21 | -10.11 | -12.34 | -4.04 | -2.83 | -1.22 |
| Net Income | -11.13 | -11.13 | -10.21 | -10.11 | -12.34 | -4.04 | -2.83 | -1.22 |
| EPS (Recurring) per share | -8.73 | -8.73 | -11.01 | -17.07 | -22.87 | -61.34 | -29.14 | -12.59 |
| EPS (Basic, Before Extraordinaries) per share | -8.73 | -8.73 | -10.98 | -14.82 | -21.45 | -41.64 | -29.14 | -12.59 |
| EPS (Diluted) per share | -8.73 | -8.73 | -10.98 | -14.82 | -21.45 | -41.64 | -29.14 | -12.59 |
| EBITDA | -11.07 | -11.07 | -9.88 | -12.03 | -13.46 | -5.58 | -2.88 | - |
| Stock Option Compensation Expense | 2.14 | 2.14+282.1% | 0.56-63.6% | 1.54-69.9% | 5.11+33.8% | 3.82+85.4% | 2.06+237.7% | 0.61 |
| Shares Outstanding million shares | - | 1.63+40.5% | 1.16+50.6% | 0.77+30.5% | 0.59+7.3% | 0.55+450.0% | 0.100.0% | 0.10 |
| Market Capitalization | 3.34 | 3.34 | - | - | - | - | - | - |
Income statement, quarterly
| Metric | 2024Q39/30/2024 | 2024Q26/30/2024 | 2024Q13/31/2024 | 2023Q412/31/2023 | 2023Q39/30/2023 | 2023Q26/30/2023 | 2023Q13/31/2023 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | - | 2.11-27.2% | 3.03-12.9% | 2.99-17.9% | 3.29-2.7% | 2.90-12.7% | 3.48-3.1% | 3.64+11.7% |
| Research and Development | - | 1.16-28.8% | 1.57-17.8% | 1.88-10.5% | 1.96+27.3% | 1.63-4.7% | 1.91+2.1% | 2.10+61.5% |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | -2.11 | -3.03 | -2.99 | -3.29 | -2.90 | -3.48 | -3.64 |
| Interest Expense | - | 0.04+300.0% | - | 2.41+677.4% | 0.00 | 0.010.0% | 1.89+4625.0% | 0.31+1450.0% |
| Unusual Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | - | -2.15-375.6% | -0.86 | -5.40 | -2.95 | 0.78 | -5.23 | -3.89 |
| Income Taxes | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | - | -2.15-375.6% | -0.86 | -5.40 | -2.95 | 0.78 | -5.23 | -3.89 |
| Net Income From Continuing Operations | - | -2.15-375.6% | -0.86 | -5.40 | -2.95 | 0.78 | -5.23 | -3.89 |
| Net Income | - | -2.15-375.6% | -0.86 | -5.40 | -2.95 | 0.78 | -5.23 | -3.89 |
| EPS (Recurring) per share | - | -2.17-288.7% | -0.95 | -7.02 | -3.84 | 1.15 | -7.67 | -6.60 |
| EPS (Basic, Before Extraordinaries) per share | - | -2.17-288.7% | -0.95 | -7.02 | -3.84 | 1.15 | -7.67 | -6.60 |
| EPS (Diluted) per share | - | -2.17-288.7% | -0.95 | -7.02 | -3.84 | 1.15 | -7.67 | -6.60 |
| Non-Operating Income (Expense) | - | 0.00-100.0% | 2.17+1450.0% | 0.00-100.0% | 0.34+47.8% | 3.69+985.3% | 0.140.0% | 0.06-89.5% |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 0.22 | 0.24 | 0.17 | - | - | - | - |
| Shares Outstanding million shares | - | 0.99+45.6% | 0.90+32.4% | 0.78+32.2% | 0.77+30.5% | 0.68+17.2% | 0.68+17.2% | 0.59+7.3% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.21-93.8% | 3.41+27.2% | 2.68-62.4% | 7.13-35.8% | 11.10+1485.7% | 0.70-22.2% | 0.90 |
| Short Term Receivables | 0.03-81.3% | 0.16-5.9% | 0.17+30.8% | 0.13-27.8% | 0.18+500.0% | 0.03+50.0% | 0.02 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.53-35.4% | 0.82+1071.4% | 0.07-41.7% | 0.12-7.7% | 0.13 | 0.00 | 0.00 |
| Total Current Assets | 0.78-82.3% | 4.40+50.7% | 2.92-60.4% | 7.38-35.3% | 11.41+1463.0% | 0.73-19.8% | 0.91 |
| Net Property, Plant & Equipment | 0.23+53.3% | 0.15-40.0% | 0.25-19.4% | 0.31+1450.0% | 0.02+100.0% | 0.010.0% | 0.01 |
| Total Investments and Advances | 0.020.0% | 0.020.0% | 0.020.0% | 0.02 | 0.00-100.0% | 0.040.0% | 0.04 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 1.03-77.5% | 4.58+43.6% | 3.19-58.6% | 7.71-32.5% | 11.43+1365.4% | 0.78-17.9% | 0.95 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.10+42.9% | 0.070.0% | 0.07+16.7% | 0.06 | 0.00 | 0.00 | 0.00 |
| Accounts Payable | 0.80-31.0% | 1.16-20.5% | 1.46+192.0% | 0.50+1150.0% | 0.04-33.3% | 0.06+200.0% | 0.02 |
| Other Current Liabilities | 1.62+113.2% | 0.76-60.6% | 1.93+66.4% | 1.16+107.1% | 0.56+700.0% | 0.07+600.0% | 0.01 |
| Total Current Liabilities | 2.52+26.6% | 1.99-42.5% | 3.46+100.0% | 1.73+188.3% | 0.60+400.0% | 0.12+200.0% | 0.04 |
| Long Term Debt | 0.07 | 0.00-100.0% | 0.07-53.3% | 0.15-91.8% | 1.83 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00-100.0% | 1.41+540.9% | 0.22 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.59+30.2% | 1.99-59.7% | 4.94+136.4% | 2.09-13.6% | 2.42+1916.7% | 0.12+200.0% | 0.04 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -1.56-160.5% | 2.58 | -1.76-131.3% | 5.62-37.6% | 9.01+1265.2% | 0.66-28.3% | 0.92 |
| Total Shareholders Equity | -1.56-160.5% | 2.58 | -1.76-131.3% | 5.62-37.6% | 9.01+1265.2% | 0.66-28.3% | 0.92 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | -1.56-160.5% | 2.58 | -1.76-131.3% | 5.62-37.6% | 9.01+1265.2% | 0.66-28.3% | 0.92 |
| Total Liabilities & Stockholders Equity | 1.03-77.5% | 4.58+43.6% | 3.19-58.6% | 7.71-32.5% | 11.43+1365.4% | 0.78-17.9% | 0.95 |
| Book Value Per Share per share | -0.96-143.2% | 2.22 | -2.29-124.0% | 9.54-42.0% | 16.46+142.4% | 6.79-28.2% | 9.46 |
| Tangible Book Value Per Share per share | -0.96-143.2% | 2.22 | -2.29-124.0% | 9.54-42.0% | 16.46+142.4% | 6.79-28.2% | 9.46 |
| Full-Time Employees people | 16+6.7% | 15-16.7% | 18+28.6% | 14+27.3% | 11+175.0% | 4 | - |
| Price to Book Ratio ratio | 0.79 | - | - | - | - | - | - |
| Return on Assets % | -397.11 | -263.45 | -185.53 | -128.94 | -66.19 | -326.18 | - |
| Return on Equity % | -2,174.98 | -2,880.11 | -523.68 | -168.75 | -83.62 | -358.66 | - |
| Return on Invested Capital % | - | -395.28 | - | -214.01 | -37.30 | -429.14 | -133.12 |
| Quick Ratio ratio | 0.31 | 2.21 | 0.84 | 4.28 | 19.12 | 6.08 | 24.68 |
| Current Ratio ratio | 0.31 | 2.21 | 0.84 | 4.28 | 19.12 | 6.08 | 24.68 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -11.13 | -11.13 | -10.21 | -10.11 | -12.34 | -4.04 | -2.83 | -1.22 |
| Depreciation | 0.02 | 0.020.0% | 0.020.0% | 0.02-77.8% | 0.09 | 0.00 | 0.00 | - |
| Deferred Taxes & Investment Tax Credit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | 2.09 | 2.09+151.8% | 0.83 | -0.18-104.5% | 3.96+77.6% | 2.23+8.3% | 2.06+237.7% | 0.61 |
| Funds from Operations | -9.02 | -9.02 | -9.35 | -10.27 | -8.29 | -1.81 | -0.76 | -0.61 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 1.34 | 1.34 | -0.78-140.8% | 1.91+154.7% | 0.75+177.8% | 0.27+285.7% | 0.07+133.3% | 0.03 |
| Cash from Operating Activities | -7.67 | -7.67 | -10.14 | -8.35 | -7.54 | -1.54 | -0.69 | -0.58 |
| Capital Expenditures | -0.01 | -0.01 | -0.00 | -0.03 | -0.07 | -0.02 | -0.01 | -0.01 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00-100.0% | 3.50 | -3.52 | 0.00 | 0.00 | -0.02 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | -0.00 | -3.52 | 0.00 | 0.00 | -0.02 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00-100.0% | 3.50 | - | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.01 | -0.01 | 0.00-100.0% | 3.47 | -3.59 | -0.02 | -0.01 | -0.03 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 4.43 | 4.43-59.4% | 10.91+174.1% | 3.98+2.8% | 3.87-63.7% | 10.66+1990.2% | 0.51-64.1% | 1.42 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 4.43 | 4.43-59.4% | 10.91+174.1% | 3.98+2.8% | 3.87-63.7% | 10.66+1990.2% | 0.51-64.1% | 1.42 |
| Proceedsfrom Stock Options | 4.41 | 4.41-59.6% | 10.91+174.8% | 3.97 | 0.00-100.0% | 0.80 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.24 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.24 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.24 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -0.10 | 0.00 | 0.00 | -0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | -0.10 | 0.00 | 0.00 | -0.00 |
| Cash from Financing Activities | 4.43 | 4.43-59.4% | 10.91+174.1% | 3.98+7.6% | 3.70-68.9% | 11.90+2233.3% | 0.51-64.1% | 1.42 |
| Exchange Rate Effect | 0.04 | 0.04 | -0.04-500.0% | 0.01 | -0.09-550.0% | 0.02 | - | - |
| Net Change in Cash | -3.21 | -3.21-533.8% | 0.74 | -0.90 | -7.52-172.6% | 10.36 | -0.19-123.5% | 0.81 |
| Free Cash Flow | -7.68 | -7.68 | -10.14 | -8.38 | -7.61 | -1.56 | -0.70 | -0.59 |
Balance sheet, quarterly
| Metric | 2024Q39/30/2024 | 2024Q26/30/2024 | 2024Q13/31/2024 | 2023Q412/31/2023 | 2023Q39/30/2023 | 2023Q26/30/2023 | 2023Q13/31/2023 | |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | - | 0.38-92.1% | 1.24-82.6% | 0.77-82.7% | 2.68-62.4% | 4.80-43.3% | 7.13-31.4% | 4.45-67.8% |
| Short Term Receivables | - | 0.41+32.3% | 0.38-11.6% | 0.42-26.3% | 0.17+30.8% | 0.31-26.2% | 0.43-39.4% | 0.57+147.8% |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | - | 0.00 | 0.00 | 0.00 | 0.07-41.7% | 0.00 | 0.00 | 0.00 |
| Total Current Assets | - | 0.79-84.5% | 1.62-78.6% | 1.19-76.3% | 2.92-60.4% | 5.11-42.5% | 7.56-31.9% | 5.02-64.2% |
| Net Property, Plant & Equipment | - | 0.18-30.8% | 0.20-28.6% | 0.23-20.7% | 0.24-22.6% | 0.26-13.3% | 0.28-9.7% | 0.29-12.1% |
| Total Investments and Advances | - | 0.020.0% | 0.020.0% | 0.020.0% | 0.020.0% | 0.02-33.3% | 0.02-50.0% | 0.02 |
| Intangible Assets | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | - | 0.98-81.8% | 1.84-76.6% | 1.45-72.8% | 3.18-58.8% | 5.39-41.6% | 7.87-31.3% | 5.33-62.9% |
| Short Term Debt Incl. Current Port. of LT Debt | - | 0.00 | 0.00 | 0.00 | 0.07+16.7% | 0.00 | 0.00 | 0.00 |
| Accounts Payable | - | 1.39+52.7% | 1.48+35.8% | 2.38+466.7% | 1.46+192.0% | 0.91+333.3% | 1.09+808.3% | 0.42+133.3% |
| Other Current Liabilities | - | 2.39+25.8% | 2.02+5.2% | 2.15+56.9% | 1.93+66.4% | 1.90+216.7% | 1.92+209.7% | 1.37+30.5% |
| Total Current Liabilities | - | 3.78+34.5% | 3.51+17.0% | 4.54+153.6% | 3.46+100.0% | 2.81+246.9% | 3.00+305.4% | 1.79+45.5% |
| Long Term Debt | - | 0.02-75.0% | 0.04-60.0% | 0.06-53.8% | 0.07-53.3% | 0.08-52.9% | 0.10-47.4% | 0.13-38.1% |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | - | 0.00-100.0% | 0.00-100.0% | 3.85+626.4% | 1.52+590.9% | 2.69+572.5% | 6.30+813.0% | 0.53-35.4% |
| Total Liabilities | - | 3.80-31.9% | 3.54-62.4% | 8.44+244.5% | 5.05+141.6% | 5.58+304.3% | 9.41+480.9% | 2.45+8.9% |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | - | -2.82 | -1.70 | -6.99-341.9% | -1.87-133.3% | -0.20-102.5% | -1.54-115.7% | 2.89-76.1% |
| Total Shareholders Equity | - | -2.82 | -1.70 | -6.99-341.9% | -1.87-133.3% | -0.20-102.5% | -1.54-115.7% | 2.89-76.1% |
| Accumulated Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | - | -2.82 | -1.70 | -6.99-341.9% | -1.87-133.3% | -0.20-102.5% | -1.54-115.7% | 2.89-76.1% |
| Total Liabilities & Stockholders Equity | - | 0.98-81.8% | 1.84-76.6% | 1.45-72.8% | 3.18-58.8% | 5.39-41.6% | 7.87-31.3% | 5.33-62.9% |
| Book Value Per Share per share | - | -2.85 | -1.89 | -8.98-283.3% | -2.44-125.6% | -0.29-102.2% | -2.27-113.5% | 4.90-77.8% |
| Tangible Book Value Per Share per share | - | -2.85 | -1.89 | -8.98-283.3% | -2.44-125.6% | -0.29-102.2% | -2.27-113.5% | 4.90-77.8% |
| Full-Time Employees people | - | - | - | - | 18+28.6% | - | - | - |
| Return on Assets % | - | -356.64 | -173.59 | -377.38 | -207.24 | -157.09 | -157.94 | -137.25 |
| Return on Equity % | - | - | - | - | -602.40 | -300.13 | -368.06 | -180.25 |
| Return on Invested Capital % | - | - | - | - | - | - | - | -128.99 |
| Quick Ratio ratio | - | 0.21 | 0.46 | 0.26 | 0.84 | 1.82 | 2.52 | 2.80 |
| Current Ratio ratio | - | 0.21 | 0.46 | 0.26 | 0.84 | 1.82 | 2.52 | 2.80 |
Cash flow, quarterly
| Metric | 2024Q3 | 2024Q2 | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 |
|---|
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 2.09% | 0.0M | 1.3M | 24.99K |
| 2026-10-15 | 2.01% | 0.0M | 1.3M | 22.54K |
| 2026-09-30 | 2.15% | 0.0M | 1.3M | 19.73K |
| 2026-09-15 | 3.06% | 0.0M | 1.3M | 18.52K |
| 2026-08-31 | 1.88% | 0.0M | 1.2M | 13.01K |
| 2026-08-14 | 1.96% | 0.0M | 1.2M | 11.28K |
| 2026-07-31 | 2.20% | 0.0M | 1.2M | 10.74K |
| 2026-07-15 | 2.35% | 0.0M | 1.2M | 7.91K |
| 2026-06-30 | 2.51% | 0.0M | 1.2M | 8.07K |
| 2026-06-15 | 2.11% | 0.0M | 1.2M | 7.89K |
| 2026-05-29 | 1.54% | 0.0M | 1.2M | 7.46K |
| 2026-05-15 | 2.04% | 0.0M | 1.2M | 8.02K |
| 2026-04-30 | 2.39% | 0.0M | 1.2M | 8.18K |
| 2026-04-15 | 2.73% | 0.0M | 1.2M | 9.39K |
| 2026-03-31 | 2.14% | 0.0M | 1.4M | 10.49K |
| 2026-03-13 | 2.10% | 0.0M | 1.2M | 11.06K |
| 2026-02-27 | 2.16% | 0.0M | 1.2M | 13.36K |
| 2026-02-13 | 1.68% | 0.0M | 1.2M | 16.64K |
| 2026-01-30 | 2.40% | 0.0M | 1.2M | 16.76K |
| 2026-01-15 | 2.46% | 0.0M | 1.2M | 16.10K |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-02 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-02 | SEC |
| 2026-10-26 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-26 | SEC |
| 2026-10-19 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-19 | SEC |
| 2026-10-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-13 | SEC |
| 2026-10-02 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-02 | SEC |
| 2026-09-25 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-30 | SEC |
| 2026-09-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-09 | SEC |
| 2026-08-27 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-27 | SEC |
| 2026-08-13 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-13 | SEC |
| 2026-08-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-08-06 | SEC |
| 2026-07-31 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-07-31 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-31 | SEC |
| 2026-07-31 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-31 | SEC |
| 2026-07-30 | F-3/A | SEC | ||
| 2026-07-22 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-22 | SEC |
| 2026-06-29 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-29 | SEC |
| 2026-06-25 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-25 | SEC |
| 2026-06-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-11 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-11 | SEC |
| 2026-06-09 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-09 | SEC |
| 2026-06-08 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-08 | SEC |
| 2026-04-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-28 | SEC |
| 2026-04-24 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-24 | SEC |
| 2026-04-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-06 | SEC |
| 2026-04-03 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-03 | SEC |
| 2026-04-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-03-26 | SEC |
| 2026-04-01 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-31 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-03-31 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-03-31 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 400.00K | 2 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Independent Advisor Alliance | 0.28% |
| Yorkville Advisors Global, LP | 0.22% |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.06% |
| PNC FINANCIAL SERVICES GROUP, INC. | 0.06% |
| UBS Group AG | 0.05% |
| Pathstone Holdings, LLC | 0.05% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.04% |
| SBI Securities Co., Ltd. | 0.03% |
| XTX Topco Ltd | 0.03% |
| Creative Planning | 0.03% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL INTERNATIONAL BOND II INDEX FUND | 514.57% |
| VANGUARD TOTAL INTERNATIONAL BOND INDEX FUND | 469.88% |
| State Street(R) SPDR(R) Bloomberg Emerging Markets Local Bond ETF | 90.24% |
| iShares International Treasury Bond ETF | 38.11% |
| iShares Core International Aggregate Bond ETF | 30.05% |
| State Street(R) SPDR(R) Bloomberg International Treasury Bond ETF | 11.10% |
| Goldman Sachs Global Core Fixed Income Fund | 7.07% |
| TCW Global Bond Fund | 0.40% |
| SA Wellington Strategic Multi-Asset Portfolio | 0.35% |
| iShares Global Government Bond USD Hedged Active ETF | 0.14% |
OakChart. NRSN. Cached 15 minutes. Terms
Some panels did not load: ratings.